Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 68, Issue 1, 2000, Pages 89-92

  Stangel, Martin ^a   Boegner, Friedrich ^a   Klatt, Christel H ^a   Hofmeister, Christoph ^a   Seyfert, Sepp ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Intravenous immunoglobulins; Multiple sclerosis; Remyelination

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MOTOR NERVE CONDUCTION; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; REMYELINIZATION;

ADULT; ANALYSIS OF VARIANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURAL CONDUCTION; PILOT PROJECTS;

EID: 0034104407     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.68.1.89     Document Type: Article

References (23)

1. Prineas JW, Barnard RO, Kwon EE, et al. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993;33:137-51.
2. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993;52:199-204.
3. Stangel M, Hartung H-P, Marx P, et al. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998;153:203-14.
4. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-93.
5. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998;50:398-402.
6. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-81.
7. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990;27:12-17.
8. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996;46:538-45.
9. van Engelen BGM, Hommes OR, Pinckers A, et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992;32: 834-5.
10. Noseworthy JH, Rodriguez M, An K-N, et al. IVIg treatment in multiple sclerosis: pilot study results and design of a placebo-controlled, double-blind clinical trial. Ann Neurol 1994;36:325.
11. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
13. Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-77.
14. Hess CW. Die mittels Kortexreizung motorisch evozierten Potentiale (MEP). In: Stöhr M, Dichgens J, Diener HC, eds. Evozierte Potentiale. Berlin: Springer, 1989:589-634.
15. Young RR, Shahani BT. Clinical value and limitations of F-wave determination. Muscle Nerve 1978;1:248-9.
16. Ludolph AC, Wenning G, Masur H, et al. Die elektromagnetische Stimulation der Nervensystems. I. Normwerte im zentralen Nervensystem und Vergleich mit der elektrischen Stimulation. Zeitschrift EEG-EMG 1989;20:153-8.
17. Sipe JC, Knobler RL, Braheny SL, et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-72.
18. Personius KE, Pandya S, King WM, et al. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther 1994;74:253-63.
19. Noseworthy JH, Weinshenker BG, O'Brien PC, et al. Intravenous immunoglobulin does not reverse recently acquired, apparently permanent weakness in multiple sclerosis. Ann Neurol 1997;42:421.
20. Noseworthy JH, O'Brien PC, Petterson TM, et al. Immunoglobulin administration does not reverse visual acuity in long-standing optic neuritis associated with multiple sclerosis. Ann Neurol 1998;44:504.
21. Asakura K, Miller DJ, Pease LR, et al. Targeting of IgMk antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci 1998;18:7700-8.
22. Dwyer JM. Manipulating the immune system with immune globulins. N Engl J Med 1992;326:107-16.
23. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104(suppl 1):3-9.